A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
about
Striving for optimal bronchodilation: focus on olodaterolDifferential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterolPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.
P2860
Q26752887-268BC253-62A0-43E5-8E36-60E66BCB34C1Q26775244-EFB51A04-9899-4A54-8428-151D60F71440Q26778685-4B8F2D33-AC44-4CB9-9717-1FB1856C500EQ33783760-D9DF8ACA-4A46-410E-9727-F767F2563144Q33890178-EE582DDA-A5CE-4ECC-80A8-0C51AF2B2C98Q34123296-6AA68081-02EF-41C9-B4C2-5A27F4D18955Q35766346-651C71D3-5A15-4A50-99E3-15E5590587C5Q35875281-560F6A17-2523-47E8-854E-11BC0471B239Q36652462-D6AE69DB-AB60-4D84-99C9-E00173E2FFCCQ39627403-9AD6EE77-8990-4922-BAE4-B8D35708153F
P2860
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@nl
type
label
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@nl
prefLabel
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@nl
P2093
P1433
P1476
A randomised, double-blind, fo ...... obstructive pulmonary disease.
@en
P2093
Alan L Hamilton
Carl Coeck
Christina Kunz
Guy F Joos
Joseph-Leon Aumann
Lawrence Korducki
René Aalbers
P304
P356
10.1016/J.RMED.2015.02.005
P577
2015-02-14T00:00:00Z